Amneal Pharmaceuticals (AMRX) News Today $8.33 +0.08 (+0.97%) Closing price 07/9/2025 04:00 PM EasternExtended Trading$8.34 +0.01 (+0.12%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AMRX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Amneal to Report Second Quarter 2025 Results on August 5, 2025July 9 at 8:00 AM | globenewswire.comBrokerages Set Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Target Price at $11.60July 4, 2025 | americanbankingnews.comAnalysts Bullish as Amneal Pharmaceuticals, Inc. (AMRX) Director Sells Over 94K SharesJuly 3, 2025 | msn.comVishria Bird Financial Group LLC Invests $350,000 in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)July 2, 2025 | marketbeat.comAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Given Average Rating of "Buy" by BrokeragesJuly 1, 2025 | marketbeat.comAmneal Pharmaceuticals, Inc. (AMRX) - Yahoo FinanceJune 28, 2025 | finance.yahoo.com5 Revealing Analyst Questions From Amneal’s Q1 Earnings CallJune 27, 2025 | finance.yahoo.comAmneal Pharmaceuticals Secures Exclusive U.S. Commercialization Rights for Biosimilar ADL-018, Targeting $3.9 Billion Omalizumab Market - NasdaqJune 26, 2025 | nasdaq.comAmneal Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish for AMRX - NasdaqJune 26, 2025 | nasdaq.comAmneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R) (omalizumab), Developed by Kashiv BioSciencesJune 25, 2025 | globenewswire.comAssenagon Asset Management S.A. Has $6.87 Million Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)June 15, 2025 | marketbeat.comHennessy Advisors Inc. Sells 171,200 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)June 14, 2025 | marketbeat.comAmneal Pharmaceuticals LLC: Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic SuspensionJune 12, 2025 | finanznachrichten.deAmneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic SuspensionJune 12, 2025 | globenewswire.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $2.52 Million Stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)June 7, 2025 | marketbeat.comGoldman Sachs initiates coverage on generic drugmakers, sees upside in Teva and AmJune 6, 2025 | au.finance.yahoo.comAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives Consensus Rating of "Buy" from BrokeragesJune 6, 2025 | marketbeat.comAmneal Pharmaceuticals (NASDAQ:AMRX) Now Covered by Analysts at The Goldman Sachs GroupJune 6, 2025 | marketbeat.comAmneal Pharmaceuticals Initiates Nationwide Recall of Contaminated Sulfamethoxazole/Trimethoprim TabletsJune 5, 2025 | msn.comAmneal Pharmaceuticals Issues Recall Due to Microbial ContaminationJune 4, 2025 | marketwatch.comAmneal Recalls Three Lots Of UTI Drug Over Concerns of Microbial Contamination: Retail Sticks To Bearish TerritoryJune 4, 2025 | msn.comSquarepoint Ops LLC Acquires 105,268 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)June 1, 2025 | marketbeat.comBank of America Corp DE Has $4.41 Million Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)May 30, 2025 | marketbeat.comAmneal to Participate at Upcoming Investor Conferences in JuneMay 29, 2025 | globenewswire.comPhocas Financial Corp. Grows Stock Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)May 28, 2025 | marketbeat.comDeutsche Bank AG Has $1.06 Million Stock Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)May 27, 2025 | marketbeat.comAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Sold by Woodline Partners LPMay 26, 2025 | marketbeat.comMan Group plc Has $965,000 Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)May 26, 2025 | marketbeat.comNuveen Asset Management LLC Has $21.67 Million Stock Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)May 26, 2025 | marketbeat.comSherbrooke Park Advisers LLC Has $97,000 Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)May 24, 2025 | marketbeat.comAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Purchased by BNP Paribas Financial MarketsMay 22, 2025 | marketbeat.comGotham Asset Management LLC Acquires 40,224 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)May 21, 2025 | marketbeat.comAmeriprise Financial Inc. Sells 49,121 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)May 21, 2025 | marketbeat.comNorthern Trust Corp Purchases 156,699 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)May 18, 2025 | marketbeat.comQuantedge Capital Pte Ltd Buys New Shares in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)May 17, 2025 | marketbeat.comAMRX Q1 Earnings Call: Miss on Revenue, Margin Expansion, and Product Pipeline ProgressMay 16, 2025 | finance.yahoo.comBalyasny Asset Management L.P. Invests $1.37 Million in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)May 16, 2025 | marketbeat.comAmneal Gets FDA Nod For Self-Administrable Migraine InjectionMay 15, 2025 | msn.comUS FDA approves Amneal's self-administered migraine treatmentMay 15, 2025 | msn.comUS FDA approves Amneal's migraine treatmentMay 15, 2025 | reuters.comAmneal Receives U.S. FDA Approval for Brekiya® (dihydroergotamine mesylate) injection for the Acute Treatment of Migraine and Cluster Headaches in AdultsMay 15, 2025 | globenewswire.comAmneal Pharmaceuticals (NASDAQ:AMRX) Downgraded to "Buy" Rating by StockNews.comMay 15, 2025 | marketbeat.comAre Options Traders Betting on a Big Move in Amneal Pharmaceuticals Stock?May 10, 2025 | msn.comAmneal and Apiject to Expand Sterile and Blow-Fill-Seal (BFS) Capabilities for Advanced Pharmaceutical Manufacturing in the U.S.May 8, 2025 | globenewswire.comAmneal Pharmaceuticals (NASDAQ:AMRX) Trading Down 5.7% - What's Next?May 7, 2025 | marketbeat.comAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Acquired by Dimensional Fund Advisors LPMay 7, 2025 | marketbeat.comAquatic Capital Management LLC Buys New Shares in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)May 5, 2025 | marketbeat.comAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Position Trimmed by Wells Fargo & Company MNMay 5, 2025 | marketbeat.comAmneal Pharmaceuticals (NASDAQ:AMRX) Announces Earnings ResultsMay 4, 2025 | marketbeat.comAmneal Pharmaceuticals (NASDAQ:AMRX) Issues FY 2025 Earnings GuidanceMay 4, 2025 | marketbeat.com Get Amneal Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMRX and its competitors with MarketBeat's FREE daily newsletter. Email Address AMRX Media Mentions By Week AMRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AMRX News Sentiment▼0.420.56▲Average Medical News Sentiment AMRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AMRX Articles This Week▼35▲AMRX Articles Average Week Get Amneal Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BBIO News Today BPMC News Today VRNA News Today ROIV News Today ELAN News Today RVMD News Today LEGN News Today GRFS News Today TGTX News Today NUVL News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AMRX) was last updated on 7/10/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredHow a Kansas farm boy gained 1,285% in two daysA former farm kid placed a simple trade… and cashed out a 1,285% gain two days later. It wasn’t crypto or a...TradeSmith | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting—or plan to collect—Social Security, this could be a game-changer. A new initiative tie...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amneal Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amneal Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AMRX Stock Alerts